NCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
Clinical Trials
138 trialsNCT04825275 2026-01-23
Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial
Milton S. Hershey Medical Center
Phase EARLY_PHASE1 Terminated
NCT04869449 2026-01-07
Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas
Milton S. Hershey Medical Center
Phase EARLY_PHASE1 Terminated
NCT04424966 2025-10-24
Infigratinib in Recurrent High-Grade Glioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Phase EARLY_PHASE1 Terminated
NCT03868943 2025-10-21
JAZZ
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01849952 2025-09-15
Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas
Dartmouth-Hitchcock Medical Center
Terminated
NCT03347617 2025-09-09
Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT04074785 2025-08-17
SCCC-06319
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Terminated
NCT04963413 2025-08-06
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
University of Florida
Phase 1 Terminated
NCT03287063 2025-07-01
Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma
University of Michigan Rogel Cancer Center
Terminated
NCT05297864 2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2 Terminated
NCT01430351 2025-05-07
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT04469699 2025-03-11
NOA11
University Hospital Muenster
Phase 2 Terminated
NCT02722512 2025-02-18
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Terminated
NCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT04397679 2025-01-15
Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT01743950 2025-01-08
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
Phase 2 Terminated
NCT04128774 2024-11-26
GBMdexaB
Amsterdam UMC, location VUmc
Terminated
NCT02372409 2024-11-01
Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors
Washington University School of Medicine
Phase 2 Terminated
NCT03973918 2024-10-31
BRAF
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT04952571 2024-10-15
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
Beijing Sanbo Brain Hospital
Phase 2 Terminated
NCT03363659 2024-10-03
Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme
Wake Forest University Health Sciences
Phase 2 Terminated
NCT01246869 2024-10-01
Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
University of Utah
Phase 1 Terminated
NCT03539731 2024-08-12
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
Stanford University
Phase 1 Terminated
NCT04221061 2024-06-17
18F-FluorThanatrace (PET/CT) in Glioblastoma
University of Pennsylvania
Phase EARLY_PHASE1 Terminated
NCT02085304 2024-04-19
Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM
St. Joseph's Hospital and Medical Center, Phoenix
Phase 1/2 Terminated
NCT03927222 2024-04-08
I-ATTAC
Duke University
Phase 2 Terminated
NCT03705351 2024-03-04
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Providence Health & Services
Phase 1 Terminated
NCT03965494 2024-02-08
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Terminated
NCT02168270 2023-11-24
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
University of Nebraska
Phase 1 Terminated
NCT02530502 2023-11-18
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Terminated
NCT04763031 2023-11-09
Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT
Parkridge Medical Center
Phase NA Terminated
NCT03939858 2023-11-08
Bioenergetic Profiling and Cognition in GBM Patients
Wake Forest University Health Sciences
Terminated
NCT02833701 2023-10-24
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
University of Nebraska
Phase 1 Terminated
NCT03593993 2023-10-06
A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Terminated
NCT01721577 2023-05-22
AXL1717
Rush University Medical Center
Phase 1/2 Terminated
NCT03714334 2023-04-07
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1 Terminated
NCT01700569 2023-02-21
FOLAGLI
Institut Cancerologie de l'Ouest
Phase 1 Terminated
NCT02664363 2023-02-17
ExCeL
Duke University
Phase 1 Terminated
NCT03430791 2023-02-02
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Baptist Health South Florida
Phase 2 Terminated
NCT02769806 2023-01-17
Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma
University of Wisconsin, Madison
Terminated
NCT00014443 2023-01-09
Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma
Rush University Medical Center
Phase 2 Terminated
NCT03119064 2022-12-13
329
Brown University
Phase 1/2 Terminated
NCT01954576 2022-10-31
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
University of Florida
Phase NA Terminated
NCT02885324 2022-10-06
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
Indiana University
Phase 2 Terminated
NCT01884740 2022-08-09
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT02663271 2022-06-23
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
University of Florida
Phase 2 Terminated
NCT02864368 2022-06-09
PERFORMANCE
Duke University
Phase 1 Terminated
NCT00669669 2022-05-18
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01925573 2022-02-03
Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)
University of Maryland, Baltimore
Phase NA Terminated